Whether subcutaneous REGEN-COV prevents severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and subsequent Covid-19 in persons at high risk for infection because of household ...

At day 29, the mean concentrations of casirivimab and imdevimab in serum were 46.4±22.5 mg per liter and 38.3±19.6 mg per liter, respectively, with the REGEN-COV 1200-mg dose and 73.2±27.2 mg ...

About the REGEN-COV Antibody CocktailREGEN-COV (casirivimab ... that was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19, using Regeneron's proprietary ...

The phase 1-2 clinical trials conducted using REGEN-COV had shown promising therapeutic benefits in COVID-19 outpatients. Its effect was further investigated in the present phase 3 clinical ...

The proportion of subjects with the reported adverse event of SARS-CoV-2 infection compared to the number of subjects at risk for infection in the REGEN-COV group and placebo group is shown here ...

The double-blind, placebo-controlled trial assessed REGEN-COV on uninfected individuals without anti-SARS-CoV-2 antibodies or any COVID-19 symptoms, who lived in the same household as an ...

REGEN-COV, which consists of the highly potent ... and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19. The two potent, virus-neutralizing antibodies ...

REGEN-COV consists of 2 potent, virus-neutralizing antibodies that bind noncompetitively to the receptor binding domain of the SARS-CoV-2 spike protein, thereby blocking its interaction with the ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) said phase 3 RECOVERY trial has shown that in patients who had not made their own antibodies against SARS-CoV-2, treating them with REGEN-COV ...

REGEN-COV rapidly protected household contacts from exposure to SARS-CoV-2 at home, with 72% protection against symptomatic infections in the first week, and 93% in subsequent weeks Among ...

Scientists harnessed AI to create mutation-resistant antibodies that outperformed conventional drug design, offering a powerful new tool against fast-evolving viruses like SARS-CoV-2. Study: AI ...